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Abstract Infection by distinct Dengue virus serotypes and host immunity are intricately linked.
In particular, certain levels of cross-reactive antibodies in the host may actually enhance infection
severity leading to Dengue hemorrhagic fever (DHF). The coupled immunological and epidemio-
logical dynamics of Dengue calls for a multi-scale modeling approach. In this work, we formulate
a within-host model which mechanistically recapitulates characteristics of antibody dependent en-
hancement (ADE) in Dengue infection. The within-host scale is then linked to epidemiological
spread by a vector-host partial differential equation model structured by host antibody level. The
coupling allows for dynamic population-wide antibody levels to be tracked through primary and
secondary infections by distinct Dengue strains, along with waning of cross-protective immunity
after primary infection. Analysis of both the within-host and between-host systems are conducted.
Stability results in the epidemic model are formulated via basic and invasion reproduction numbers
as a function of immunological variables. Additionally, we develop numerical methods in order to
simulate the multi-scale model and assess the influence of parameters on disease spread and DHF
prevalence in the population.
Keywords Dengue hemorrhagic fever (DHF) · antibody dependent enhancement (ADE) ·
multi-scale · immuno-epidemiological model · size-structured partial differential equation (PDE) ·
invasion stability analysis
1 Introduction
The global burden of Dengue infection has rapidly increased in recent years, with about 400 million
dengue infections occurring every year. Research has delved into the complexities of this mosquito-
transmitted disease. The intricate relationship between host immune response, pathogenesis, viral
diversity and epidemiology has received particular attention. While the immune response ultimately
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clears Dengue virus from an infected host and provides strain-specific immunity upon recovery,
certain levels of cross-reactive antibodies (reacting to multiple Dengue strains) may actually enhance
severity of a subsequent (or even a primary) infection manifesting in Dengue hemorrhagic fever
(DHF). Determining the impact of host immune response, distinct viral strains, and population-
wide antibody levels on Dengue incidence calls for a multi-scale approach. The problem is critical for
control strategies against Dengue, highlighted by recent debate over vaccination, which by boosting
antibody responses, may actually increase DHF prevalence in certain groups. Herein this paper, we
develop a mathematical model linking within-host and between-host scales through host antibody
level in order to describe the connection between immunity and Dengue infection dynamics across
both scales.
Dengue fever is caused by four antigenically related but distinct serotypes (DENV-1 to DENV-
4). Infection by one serotype confers life-long immunity to that serotype and a period of tempo-
rary cross-immunity to other serotypes. Sequential infection increases the risk of developing severe
dengue, due to a process described as antibody-dependent enhancement (ADE), where the pre-
existing antibodies to previous dengue infection enhances the new infection [12]. The mechanisms
behind ADE and consequences on Dengue epidemiology are not completely understood. However,
recent research has found evidence that a certain intermediate window of pre-existent antibody
titer in the host population is associated with risk of DHF [23,33].
Previous modeling efforts have studied Dengue infection on either the within-host or between-
host scales [7,39,16]. Several mathematical models investigate multi-strain epidemiological dynam-
ics with potential secondary infection and ADE due to partial or temporary cross-reactivity [3,15,
31,27]. Resulting bi-stable, oscillatory or chaotic dynamics may explain large fluctuations in disease
incidence observed in Dengue epidemics [15,11,2]. In all of these epidemic models, ADE is incorpo-
rated through parameters associated with secondary infection, however the recent evidence points
to pre-existent antibody levels as the determinant of infection severity. Therefore for a more precise
formulation of ADE on the epidemiological scale, a model should track dynamic immune status in
host population, which is one of the goals of this paper. On the within-host scale, several mod-
els have considered the phenomenon of ADE [7,19,28], although explicit dependence of infection
severity on pre-existent cross-reactive antibody concentration has not been produced.
In addition to the correlation of pre-existent antibody level to risk of developing severe infec-
tion, the virus and antibody dynamics within infected hosts determine their inherent infectivity
and recovery rates. With this in mind, multi-scale models linking within-host and between-host dy-
namics emerge as an appropriate tool for a unified model of Dengue. In particular, recently studied
“nested immuno-epi” models offer a useful framework, where a partial differential equation (PDE)
epidemiological model includes a structuring variable that also appears on the virus-immune re-
sponse scale [18,17,36,20]. In most nested models, transmission and recovery rates of infected hosts
are structured by infection-age τ depending upon pathogen and immune concentrations within-host
τ units after infection, independent of the epidemic scale and with identical infection course among
all hosts. Recently, more complex scenarios have also been considered, such as a distribution of
immunity among susceptible hosts [30] and a “pathogen size- structured” epidemic model with
fully coupled feedback through variable initial pathogen load [17]. In addition, without explicitly
modeling the within-host scale, several works have explored dynamic levels of host immunity in
delay differential equation (DDE), PDE, and stochastic epidemic models with re-infection, immune
boosting and waning [25,6,37,13].
Dengue provides a particular example where host immunity has complex and significant effects
on infection dynamics across both within-host and between-host scales. Therefore, in this paper, we
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construct immunological and epidemiological models that capture signatures of ADE on both scales,
connected via a variable tracking host cross-reactive antibody levels through multiple infections by
distinct strains, along with recovery and waning. First, we formulate a within-host model which
mechanistically mimics characteristics of ADE in Dengue infection; namely (i) a shorter time to
peak viremia, (ii) a higher maximum viral clearance rate, (iii) a higher peak viremia [7], and (iv)
infection severity (measured by peak viremia) modulated by initial antibody concentration with a
unimodal relationship [23,33]. Moreover, we prove that our formulation is, in a sense, the minimal
model to produce severe infection solely by varying pre-existent antibodies in an intermediate
window of concentration. Next, the within-host scale is linked to epidemiological spread by a PDE
model structured by host antibody level. Stability results in the epidemic model are formulated via
basic and invasion reproduction numbers as a function of immunological variables. Additionally, we
develop numerical methods in order to simulate the multi-scale model and assess the influence of
ADE on disease spread and burden in the population. Overall our model offers a very promising
approach for understanding the connection between immunity and Dengue infection dynamics on
both within-host and population scales.
2 Multi-Scale Dengue Modeling: An Antibody Size-Structured Approach for
Sequential Infections
2.1 Within-host model and analysis
Here we formulate a within-host model which can describe primary and secondary Dengue infec-
tions, along with the host immune response. We attempt to simplify the within-host dynamics of
virus and immune response, while still capturing the mechanisms responsible for Antibody De-
pendent Enhancement (ADE) of the infection. In order to model the host immune response, we
consider long-lived memory antibodies (IgG) as proxies for the collective immune populations (which
includes short-lived innate and IgM antibody responses, along with T-cell responses). The mem-
ory antibodies increase upon infection, and can roughly be grouped into two categories, specific
and cross-reactive (non-specific). Distinct antibody populations target several epitopes (viral pro-
teins) during infection, some of which are common amongst the different Dengue serotypes while
other epitopes are specific to the infecting strain. The former are often termed (sero-)cross-reactive
antibodies and have less affinity to the infecting virus than the more specific antibodies. This dis-
tinction is important as during secondary infection, or even possibly primary infection, pre-existent
cross-reactive antibodies within the host may induce ADE.
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Table 1 Description of the within-host model variables/parameters in (1) and value chosen for simulations (which
mimic qualitative within-host characteristics of Dengue)
Variable/Parameter Description Value
x(τ) Dengue virus concentration at τ days post host infection –
y(τ) concentration of cross-reactive (IgG) antibodies at host infec-
tion age τ
–
z(τ) concentration of specific antibodies at host infection age τ –
r Within-host virus growth rate 1
α1 Viral growth enhancing rate induced by cross-reactive
antibody-virus binding (ADE)
2
α2 Cross-reactive antibody-virus killing rate upon cooperative
binding
3
δ Specific antibody-virus killing rate upon binding 3.5
φ1 Cross-reactive antibody activation rate 0.4
φ2 Specific antibody activation rate 0.5
k1, k2 Antibody interference competition coefficient 0.1, 0.1
A1, A2, C1 Saturation coefficients of Hill functions for cross-reactive anti-
body
1, 10, 10
B,C2 Saturation coefficients of Hill functions for specific antibody 1, 10
Consider the infecting virus strain, x(τ), specific IgG response to this strain, z(τ), and the cross-
reactive (non-specific) IgG response, y(τ), where the time variable τ refers time-since-infection
within a host. The virus is assumed to undergo exponential growth at the rate r for simplicity,
and the specific IgG response z(τ) kills the virus and proliferates according to Michaelis-Menten
kinetics. There are multiple mechanisms for ADE which we include in our model. First, studies
have shown that neutralization of a virion requires more bound cross-reactive antibodies compared
to the specific response [12]. Thus, we model the neutralization by cross-reactive response y(τ)
with a sigmoidal Hill equation of “n = 2” positive cooperativity [34], as opposed to “n = 1”
Michaelis-Menten kinetics. In this way, a threshold number of cross-reactive antibodies bound to a
virion is required for neutralization and so low concentrations of cross-reactive antibodies have poor
neutralization properties, consistent with a “multiple-hit” stoichiometry requirement hypothesis [38,
32,14]. Furthermore, any antibody-virion binding can actually enhance probability of cell infection
[12], and thus we add a Michaelis-Menten enhancing term dependent on cross-reactive antibodies
y(τ) to the viral replication rate. Note that the efficient neutralization by specific antibodies with
higher affinity to virions precludes the need to add a similar enhancing term for z(τ). Another
possible mechanism of ADE is “original antigenic sin” where antibody populations compete and
interfere with each other [29]. This is included by interference competition coefficient k1 and k2
inhibiting the proliferation rates of y and z. With these features in mind, the following Dengue
within-host model is novel for its enzyme kinetics mechanisms of ADE.
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Within-host Model

dx
dτ
= x
(
r +
α1y
A1 + y
− α2y
2
A2 + y2
− δz
B + z
)
:= f(x, y, z)
dy
dτ
=
φ1xy
C1 + y + k1z
:= g(x, y, z)
dz
dτ
=
φ2xz
C2 + k2y + z
:= h(x, y, z)
(1)
The initial conditions x(0) = x0, y(0) = y0, and z(0) = z0 and all parameters are assumed to be
non-negative.
We remark that the assumed exponential growth of the virus in the absence of immune response
is a simplification of viral replication dynamics. In reality there is a source of target cells which
is depleted (and has recruitment), which bounds the virus population dynamics. Target cells have
been included in previous models of Dengue infection [7]. For simplicity, we assume in our model
that immune suppression of the virus either overwhelms or is more important than any effect of
target cell limitation on the dynamics. Also, here and as been found in other studies, immune
response is necessary to clear Dengue virus [10]. The following theorem shows that in our model
the immune response is sufficient to clear the virus.
Proposition 1 Suppose that δ > r + α1 and α2 > r + α1 in system (1). If y0 > 0 or z0 > 0, then
lim
τ→∞x(τ) = 0, limτ→∞ y(τ) = y¯, limτ→∞ z(τ) = z¯ where y¯, z¯ depends on initial conditions.
Proof Since the boundary of the positive orthant, ∂R3+, is invariant for (1), we find that R3+ is also
invariant. Thus solutions remain non-negative for all τ . Also it is not hard to show that solutions
exist for all τ since the differential inequality (x+ y + z)
′ ≤ c (x+ y + z) can be established for
appropriate constant c, which yields an exponential bound for the solution.
Now suppose by way of contradiction that lim sup
τ→∞
x(τ) > 0. Let w = y + z and observe that
w′ ≥ φxwC+kw , where φ = max(φ1, φ2) and C = min(C1, C2). Integrating, we find C ln
(
w(τ)
w0
)
+
w(τ) − w(0) ≥ φ ∫ τ
0
x(s)ds. Thus lim
τ→∞w(τ) = ∞. Therefore, since δ > r + α1 and α2 > r + α1,
there exists τ∗ : ∀τ > τ∗, where r + α1y(τ)
A1 + y(τ)
− α2y(τ)
2
A2 + y(τ)2
− δz(τ)
B + y(τ)
< 0. Integrating the
first equation in (1), we find x(τ) = x0 exp
(∫ τ
0
(
r +
α1y(τ)
A1 + y(τ)
− α2y(τ)
2
A2 + y(τ)2
− δz(τ)
B + z(τ)
)
ds
)
.
Since the integrand is negative for τ > τ∗, we conclude lim
τ→∞x(τ) = 0. Next, since 0 ≤ y
′(τ), y(τ)
is increasing, it has either positive limit or diverges to infinity asymptotically. Suppose by way of
contradiction that lim
τ→∞ y(τ) = ∞. Then
dx
dτ ≤ −ax(τ) for τ sufficiently large, say τ ≥ τ0, where
a = α2 − (r + α1) +  > 0 for some  sufficiently small. Thus x(τ) ≤ x(τ0)e−a(τ−τ0), and thus
y′ ≤ φ1xy
C1 + y
≤ φ1x
C1
⇒ y(τ)− y(τ0) ≤ φ1
C1
∫ τ
τ0
e−a(τ−τ0)dτ.
Therefore y(τ) is bounded and there exists y¯ > 0 such that lim
τ↗∞
y(τ) = y¯. Similarly z(τ) converges
monotonically to a limit z¯.
6 Hayriye Gulbudak, Cameron J. Browne
(a) (b)
(c) (d)
Fig. 1 (a) Example trajectory of within-host model (1). (b) Cross-reactive antibody levels (y or y0) are boosted
during primary infection and then wane to an intermediate level which can produce severe infection upon secondary
infection due to ADE effect. (c) Host infection severity (peak viral load) unimodal function of pre-existent antibody
level (y0). (d) Two orbits corresponding to solutions of within-host model (1). The parameters (and initial conditions)
of within-host model (1) are set as follows: (a) y0 = 0.11; (b) y0 = 0.11 for primary infection and y0 = 0.5 for
secondary infection (after 2 years of antibody exponential decay given by waning rate (9) with ξ = 0.002, yc = 0.02;
(c) y0 varied in range [0.01, 2.5]; (d) y0 = 0.11 and y0 = 0.3. All other parameters are fixed at r = 1, α1 = 2, A1 =
1, α2 = 3, A2 = 10, δ = 3.5, B = 1, φ1 = 0.4, φ2 = 0.5, C1 = C2 = 10, k1 = k2 = 0.1, and x0 = 0.01, z0 = 0.1.
The trajectory of the virus population mimics the general pattern displayed in data of rise and
subsequent decline of virus caused by immune response, characteristic of an acute infection. We
obtain a triangular curve in log scale of viral load as found in other studies [7], and Proposition 1
shows that the virus population converges to zero while (memory) immune responses saturate to an
equilibrium level dependent on initial concentrations. Moreover the within-host model mechanisti-
cally mimics characteristics of ADE in Dengue infection; namely (i) a shorter time to peak viremia,
(ii) a higher maximum viral clearance rate, (iii) a higher peak viremia [7], and (iv) infection severity
(measured by peak viremia) modulated by initial antibody concentration with a unimodal relationship
[23,33]. Note that fitting the within-host model to data is not a goal of the present work. However,
we do tune parameters in system (1) to first match infectious period of primary infection (Figure
1(a)), and after a characteristic period where cross-reactive antibodies, y, wane to a certain range,
subsequent secondary infection displays features (i)-(iii) associated with DHF induced by ADE, as
shown in Figure 1(b).
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The system (1) captures the signature of Dengue infection severity being highest for intermediate
pre-existent antibody level ((iv) in previous paragraph), and is, in some sense, the minimal model
to produce this unimodal relationship, as the following proposition suggests:
Proposition 2 Consider system (1) with δ > r + α1 and α2 > r + α1. Let x(τ ; y0) denote the
viral component of solution as a function of initial cross-reactive antibody level y0, and xM (y0) :=
maxτ≥0 x(τ ; y0) denote the peak viral load as a function of y0 (with other parameters fixed). Then
there exists some set of parameters for the system (1) where xM (y0) is an unimodal curve with a
single maximum, in particular when φ1 = k2 = 0, A2 = 3, C2 = B, and A1 >
8α1
3α2
. Furthermore, if
z = 0 (y = 0), then xM (y0) (xM (z0)) will be a strictly decreasing function.
Proof In order to prove the first statement, consider the special case where φ1 = 0, for simplicity,
since we just need to show it for some parameter set. In this case the cross-reactive antibody
concentration y does not change during infection, i.e. y(t) ≡ y0. Then the infection dynamics are
dx
dτ
= x
(
r(y0)− δzB+z
)
dz
dτ
=
φ2xz
C(y0) + z
,
(2)
where r(y0) = r +
α1y0
A1+y0
− α2y20
A2+y20
and C(y0) = C2 + k2y0. We assume that α2 > r + α1 as in
Proposition 1. We first claim the function r(y0) is unimodal. Since r
′(y0) = α1A1(A1+y0)2 −
2α2A2y0
(A2+y20)
2 , we
find the following polynomial equation for the roots of r′(y) (which are the critical points of r(y)):
α1A1y
4 − 2α2A2y3 + 2A1A2(α1 − α2)y2 − 2A2A21α2y + α1A1A22 = 0. (3)
Since α1 − 2α2 < 0 by assumption, there are either two or zero positive roots by Descarte’s rule
of signs. We now find parameters where there are two positive roots, y∗1 < y
∗
2 . Let p(y) =
α1A1
(A1+y)2
and q(y) = 2α2A2y(A2+y2)2 , and observe that r
′(y) = p(y) − q(y). Note that p(0) = α1A1 > 0, p(y) is
decreasing, q(0) = 0 and q′(0) > 0. The goal is to obtain conditions where max
y>0
q(y) > p(0) which
would guarantee intersection of p(y) and q(y), and hence a positive root. It can be shown that
q′(y) = 0 ⇒ A2 + y − 4y2 = 0. Let A2 = 3, then the maximum of q(y) occurs at yˆ = 1, and
q(1) = 38α2 >
α1
A1
= p(0) if A1 >
8α1
3α2
. Thus if A1 = A2 = 3, then there are two positive roots.
Furthermore since r′(0) > 0, y∗1 is a local maximum of r(y) and y
∗
2 is a local minimum. Also
r(∞) < 0 implies that there exists unique positive root y of r(y), where r(y) > 0 for 0 ≤ y < y and
r(y) < 0 for y > y (where y < y∗2). Clearly if y0 > y, then x˙(t) < 0 for all t ≥ 0, so xM (y0) = x0
in this case. Furthermore we show that peak viral load xM (y0) is increasing with respect to the
growth rate r(y0) for the special case k2 = 0, C2 = B. Indeed in this case, peak viral load occurs at
zc(r) :=
rB
δ−r , and dividing equations in (2)
dz
dx
=
φ2z
rB + (δ −B)z ⇒
∫ zc(r)
z0
dz
(
rB
φ2z
+
δ −B
φ2
)
=
∫ xM (r)
x0
dx
⇒ x′M (r) =
Bδ
(δ − r)2
(
δ − r
φ2
+
δ −B
φ2
)
> 0
Therefore it follows that the peak viral load xM (y0) is unimodal with a single maximum.
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Now to show the second statement. For given parameters satisfying δ > r+α1 and α2 > r+α1
with either z = 0 or y = 0, Proposition 1 implies the pathogen load will tend to zero while the
single present antibody population is increasing. Viewed in the phase plane of pathogen (x) and
single antibody population (without loss of generality, y), the orbits form arcs connecting initial
antibody level, y0, with final antibody level y
∗(y0) = lim
τ→∞ y(τ ; y0) > y0, as x increases to peak
and decays to zero. When increasing initial antibody level, y0, in order for the peak viral load to
increase, solutions would have to cross violating flow property of solutions. Thus peak viral load
can then only be a decreasing function of initial antibody load in this case.
Proposition 2 implies that the presence of both cross-reactive and specific antibodies within
infection are necessary to produce the ADE phenomenon of severe infection for intermediate level
of pre-existing antibodies. The full model (1) with both antibody types produces the unimodal
curve for infection severity versus initial antibody load (Fig. 1(c)), similar to data from recent
epidemiological studies. Observe in Fig. 1(d), the “crossing” of two solution projections on the xy-
plane when both antibody components y, z are present and y0 is varied. In contrast, Proposition 2
states that peak viral load cannot increase with y0 when z = 0. Moreover sufficient conditions to
generate the unimodal pattern are dominance of (cross-reactive) antibody enhanced viral infection
rate at low concentrations (controlled by A1) switching to dominance of neutralization at higher
concentrations (controlled by α2), consistent with the observed mechanisms responsible for ADE
in experiments [12].
2.2 Between-host model and linking scales
Here we detail our antibody structured vector-host epidemiological model which links to the within-
host model, tracking evolving antibody levels as illustrated in Fig. 2. Let s(t, y), ik(t, y, y0), rk(t, y),
ikj(t, y, y0), rkj(t, y) be the density with respect to (cross-reactive) antibody level y (and initial
antibody level y0 at time of infection) at time t, of susceptible, primary strain-k infected, primary
strain-k infection recovered, secondary strain-j infected hosts, and secondary infected recovered
individuals, respectively. In the vector model, we consider Sv(t), Iv(t) as the number of susceptible
and infected vectors, respectively. Vectors are the only mechanism transmitting the disease to
susceptible hosts. The host compartments structured by antibody levels, y, can be integrated over
y (and y0 in the case of infected classes) in order to obtain the number of individuals in each
compartment. For example, the number of susceptible individuals is given by S(t) =
∞∫
0
s(t, y) dy
and the number of individuals infected by strain k is
∞∫
0
∞∫
y0
ik(t, y, y0) dy dy0. The epidemiological
dynamics is given by the following vector-host model:
∂s(t, y)
∂t
= Λ(y)− s(t, y)
∑
k
βkv (y)I
k
v (t)− µs(t, y) (4)
∂ik(t, y, y0)
∂t
+
∂(gk(y, y0)ik(t, y, y0))
∂y
= − (γk(y, y0) + µ) ik(t, y, y0) (5)
∂rk(t, y)
∂t
− ∂(ωk(y)rk(t, y))
∂y
=
∫ ∞
0
γk(y, y0)ik(t, y, y0)dy0 − µrk(t, y)− βjv(y)rk(t, y)Ijv(t)
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∂ikj(t, y, y0)
∂t
+
∂(gkj(y, y0)ikj(t, y, y0))
∂y
= − (γkj(y, y0) + µ) ikj(t, y, y0)
∂rkj(t, y)
∂t
− ∂(ωkj(y)rkj(t, y))
∂y
=
∫ ∞
0
γkj(y, y0)ikj(t, y, y0)dy0 − µrkj(t, y), k 6= j,
dSv
dt
= Λv − Sv
2∑
k=1
∞∫
0
∞∫
y0
βk(y, y0)ik(t, y, y0) dy dy0 − Sv
2∑
k,j=1
k 6=j
∞∫
0
∞∫
y0
βkj(y, y0)ikj(t, y, y0) dy dy0 − µvSv
dIkv
dt
= Sv
∞∫
0
∞∫
y0
βk(y, y0)ik(t, y, y0) dy dy0 + Sv
∞∫
y0
∞∫
y0
βjk(y, y0)ijk(t, y, y0) dy dy0 − µvIkv , (6)
with the following boundary conditions
gk(y0, y0)ik(t, y0, y0) = β
k
v (y0)s(t, y0)I
k
v (t), ωk(yc)rk(t, yc) = lim
y→∞ωk(y)rk(t, y) = 0, (7)
gkj(y0, y0)ikj(t, y0, y0) = β
j
v(y0)rk(t, y0)I
j
v(t), ωkj(yc,2)rkj(t, yc,2) = lim
y→∞ωkj(y)rkj(t, y) = 0, k 6= j,
and the following initial conditions
s(0, y0) = s0(y0), y0 ≥ ys ≥ 0, ik(0, y, y0) = i0k(y, y0), y ≥ y0 ≥ ys (8)
rk(0, y) = r
0
k(y), y ≥ yc ≥ 0, ikj(0, y, y0) = i0kj(y, y0), y ≥ y0 ≥ yc,
rkj(0, y) = r
0
kj(y), y ≥ yc ≥ 0, Sv(0) = S0v , Iv(0) = I0v .
The host initial conditions are assumed to be non-negative (Lesbesgue) integrable functions,
i.e. in L1+, on their domains specified above, and vector initial conditions are non-negative, i.e.
S0v , I
0
v ∈ R+. The parameters Λ(y) and Λv denote the host and vector recruitment rates, and
µ and µv represents the host and vector natural death rates, respectively. The vector to host
transmission rate may depend on the host antibody level, so in general we have this rate as βkv (y). We
assume Λ(y) and βkv (y) are bounded, measurable non-negative functions, i.e. in L
∞
+ (0,∞). The other
parameter functions linking antibody levels y and y0 to epidemiological quantities will be detailed
in following paragraphs. First note that assumptions may be relaxed at times to allow for point
measure distributions, e.g. all susceptible individuals have the same initial naive amount of cross-
reactive antibodies, ys, so that Λ(y) = Λδ(ys), s0(y) = S0δ(ys) where δ(y) is the Dirac delta measure
at y, and Λ is constant. In this case, we can consider an ODE for S(t) :=
∫∞
0
s(t, y)δ(ys)dy = s(t, ys).
Also, we remark that the secondary recovered component, rkj , decouples from the rest of the system.
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waning
Fig. 2 Schematic diagram of multi-scale Dengue model (4)-(6) viewed through evolving host antibody level.
Table 2 Definitions of the between-host model variables
Variable Description
s(t, y) density of susceptible hosts at time t with (cross-reactive) antibody level y,
ik(t, y, y0) density of primary strain-k infected hosts at time t with antibody level y and pre-
existent antibody level y0,
rk(t, y) density of strain-k recovered hosts at time t with antibody level y,
ikj(t, y, y0) density of secondary strain-j infected hosts at time t with antibody level y and
pre-existent antibody level y0,
Sv(t) number of susceptible vectors at time t,
Iv(t) number of infected vectors at time t,
Table 3 Definition of the between-host model parameters
Parameter Meaning Values (range)
Λ(y) recruitment rate of susceptible hosts with antibody
level y
E(Λ) = 100 (variable dis-
tribution centered around
ym = 0.11)
Λv susceptible vector recruitment rate 0.02
βkv (y) transmission rate from k-strain infected vector to
susceptible hosts with antibody level y
{
0.00025 y < yp
0 y > yp
βk(y, y0) transmission rate from primary strain-k infected
hosts, with antibody level y (and initial antibody
level y0), to susceptible vectors
a
βkj(y, y0) transmission rate from secondary strain-j infected
hosts, with antibody level y (and initial antibody
level y0), to susceptible vectors
a
γk(y, y0) recovery rate of primary strain-k infected hosts,
with antibody level y (and initial antibody level y0)
a
γkj(y, y0) recovery rate of secondary strain-j infected hosts,
with antibody level y (and initial antibody level y0)
a
gk(y, y0) antibody growth rate (
dy
dτ in (1)) during primary
infection
a
gkj(y, y0) antibody growth rate (
dy
dτ in (1)) during secondary
infection
a
ωk(y) (cross-reactive) antibody waning rate after primary
infection
a
ωkj(y) (cross-reactive) antibody waning rate after sec-
ondary infection
a
µ Host natural death rate 1/(10×365), 1/(55×365)
µv Vector natural death rate 1/20
a see Table 1 & 4, along with linking functions (10), (10), and (13).
Title Suppressed Due to Excessive Length 11
The functions gk(y, y0) and gkj(y, y0) represent the memory antibody concentration growth
rates corresponding to primary infection with strain k and secondary infection by strain j, respec-
tively. They can be formally defined as follows. Consider the solution to the within-host system
(1) with parameters corresponding to the particular infection type (strain and primary/secondary).
Note that within the general within-host model (1), parameters may differ between strain and
whether it is primary or secondary infection. Given the solution x(τ) := x(τ ;x0, y0, z0), y(τ) :=
y(τ ;x0, y0, z0), z(τ) := z(τ ;x0, y0, z0), define inverse map τ = τ(y; y0) corresponding to time since
infection, noting that y(τ ; y0) is strictly increasing function of τ for each y0 > 0 (holding x0, z0
fixed). For primary or secondary infection, we assume fixed initial concentration of pathogen x0
and fixed initial specific naive (memory) specific antibody concentration of z0 > 0. The initial
cross-reactive antibody concentration, y0 = y˜, is given by the structuring variable of the sus-
ceptible host which becomes infected, s(t, y˜), in the case of primary infection. Then gk(y, y0) =
g(x(τ ;x0, y˜, z0), y(τ ;x0, y˜, z0), z(τ ;x0, y˜, z0))) where g is the second component of the vector field
in the within-host system (1) with parameters corresponding to primary infection by strain k. Sim-
ilarly gkj(y, y0) = g(x(τ ;x0, y˜, z0), y(τ ;x0, y˜, z0), z(τ ;x0, y˜, z0)) with parameters corresponding to
secondary infection by strain j in system (1).
Multiple studies have shown that following primary infection, individuals have a temporary
period of immunity to different serotypes induced by cross-reactive antibodies primed by the pri-
mary infecting serotype. This immunity can be generated in our within-host models via the rise
of antibody concentration during primary infection to levels sufficient for inhibition of secondary
infection. However, in reality the immunity can wane through time allowing for secondary infection
by serotypes distinct from the primary strain, potentially manifesting in dengue hemorrhagic fever
caused by ADE at intermediate levels of cross-reactive antibody. Note that although the antibody
level wanes through time, recovered individuals remain immune to the primary infecting strain,
thus the total antibody levels (in particular specific antibodies) stay above some critical level for
strain-specific immunity. With these features in mind, we include a drift term for waning antibody
level. Suppose that antibody levels change according to y˙ = −ωk(y), where ωk ≥ 0 is the rate of
antibody waning after recovery from primary infection by strain k. We assume that ωk(y) → 0
as y → y+c , so antibody levels stay above some yc ≥ 0, as studies show that antibodies do not
wane completely. Similar assumptions are made for individuals recovered from secondary infection,
however since they have permanent immunity to both strains, the rkj equation is decoupled from
the system. A specific example, supported by a study of waning IgG [5], is exponential decay of
memory antibodies, above the critical level yc:
ωk(y) = ξ(y − yc), so that y(τ) = (y0 − yc)e−ξτ + yc. (9)
This exponential rate form is utilized in between primary and secondary infection in Fig. 1(b) with
ξ and yc calibrated to produce the displayed waning antibody level in the characteristic period of
2 years corresponding to loss of cross-immunity [31].
On the host population scale, the preexistent cross-reactive antibody level, y0, can vary accord-
ing to the distribution Λ(y0), leading to variable within-host primary infection dynamics in the
population. The recovery and waning process creates more heterogeneity in antibody level among
the host population, leading to variable responses to secondary exposure. In order to formulate the
recovery rate, first note that Dengue is an acute infection with an approximate triangular viral load
trajectory in log scale, suggested by both data and our within-host model. In addition, recovery
from primary infection induces lifelong immunity to the primary infecting serotype. With these
features in mind, we consider a few possible recovery rate forms. First, we assume the recovery rate
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(a) (b)
Fig. 3 (a) Transmission rate, β`(τ(y, y0)), and probability of exiting infectious period (through recovery or death),
given by 1 − pi`(τ(y, y0)), as functions of time since infection τ = τ(y, y0). (b) Infection severity (as shown in Fig.
1(c)) and host-vector force of infection Fk(y0) as functions of pre-existent antibody level y0. The parameters utilized
for the within-host model (1) are the same as Fig. 1 with y0 = 0.11 for (a). For the linking functions, β(τ(y, y0)) and
γ(τ(y, y0)), we utilize (13) with ψ = 0.001 and C` = 135 (based on [26]), and (10) with ρ = ν = 10, respectively.
increases as viral load slope becomes negative and the viral load becomes small. The second rate
form specifies that viral load should be decreasing, i.e. viral load slope becomes negative, which
is a necessary condition for protective immunity against the same strain. Last, we suppose that
recovery occurs at a fixed level of antibody. In particular, we give the following three examples of
recovery rates;
(i) γk(τ(y, y0)) = e
−(ρx(τ)+ν(log x(τ))′), (10)
(ii) γk(τ(y, y0)) = νe
−ρx(τ)1{fk(τ)<0}, (11)
(iii) γk(y, y0) = δ(y − y∗(y0)), (12)
where ρ, ν are factors determining the distribution of recovered hosts with respect to infection
dynamics and fk(τ) = fk(x(τ), y(τ), z(τ)) is the pathogen growth rate. For (ii), note that γ is zero
prior to the critical time when the pathogen begins to decrease (when fk(τ) = 0). For (iii), y
∗
corresponds to a constant antibody level dependent on initial conditions at which infected hosts
recover. Note that this case covers the situation where the virus must decline below a fixed threshold,
x∗, which can be related to y∗ via the inverse map. Also for (iii), the infectious period for strain-k
infected hosts with initial level y0 is given by T (y0) =
1∫ y∗(y0)
y0
gk(y,y0)dy
.
The host to vector transmission rate also depends upon the within-host infection dynamics. Data
suggest that the probability of an mosquito getting infecting by a bite from an infected individual
is a Holling type III function of the pathogen load at a given time-since-infection τ ([22], [26],[36]).
Thus, the form of host to vector transmission rate utilized is as follows;
β`(y, y0) = ψ
(x(τ(y, y0)))
2
C` + (x(τ(y, y0)))2
, ` ∈ {1, 2, 12, 21} (13)
where C`, and ψ are half saturation and transmission constants. We utilize data of DENV-1 from
[26] in order to parameterize the half-saturation constant C := C`. In particular, although we do
not concern about the scale of viral load in our simulations (e.g. Fig. 1(a)), C is chosen so that the
ratio of peak viral load and viral load causing 50% infectiousness does match the data in [26]. Both
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the transmission rate, β`(τ(y, y0)), and probability of exiting infectious period (through recovery
or death), given by 1− pi`(τ(y, y0)) (defined later by formula (15)), are simulated in Fig. 3(a).
Table 4 Description of linking parameters in (10), (10), and (13).
Parameter Description Value
ψ max host-vector transmission rate 0.001 a
C host-vector transmission saturation constant 135 a
ρ host recovery shape parameter for viral load 10
ν host recovery shape parameter for viral load slope 10
ξ antibody waning rate 0.002 b
yc antibody lower bound 0.02
b
a Chosen to match data in [26].
b Corresponds to approximately 2 years before recovered primary are susceptible to severe sec-
ondary infection.
Remark 1 Finally, we remark that the host population can be equivalently structured by both
antibody variables y and z. Then, for example, the following equation for i˜k := i˜k(t, y, z, y0, z0)
would appear:
∂i˜k
∂t
+
∂(gk i˜k)
∂y
+
∂(hk i˜k)
∂z
= −γk i˜k (14)
(gk(y0, z0, y0, z0) + hk(y0, z0, y0, z0))˜ik(t, y0, z0, y0, z0) = β
k
v (y0, z0)s(t, y0, z0)I
k
v (t)
In such a model, y might be interpreted as antibodies specific to strain 1 and z as antibodies
specific to strain 2. In this way, the model affords flexibility in terms of how one defines specific
versus non-specific antibodies. While tracking multiple antibody variables may seem to complicate
matters, observe that there is a 1-1 relationship between y and z, where the additional variable z
is mapped onto y via the inverse map. Thus we can utilize our original system (4) (with additional
“static” variable z0) and simply calculate z(y) for each cohort. Note also that the infection-age τ
is in 1-1 relationship with y, therefore we can transform the system to an age-structured model
as done in [17]. However since we are interested in tracking antibody level in host population, we
only pursue this direction when it can be advantageous for numerical simulations in the special case
when susceptible antibody level (Λ(y), s0(y)) is a Dirac point measure distribution (see Section 5) .
3 Analysis of between-host model
The aims of this paper are multi-scale model formulation, and equilibrium, linearized stability and
numerical analysis, with the goal of capturing Dengue ADE across scales. We do not delve into
establishing existence, uniqueness, regularity and positivity of solutions of (4)-(6). However, in a
sequel to this paper, we will analyze the uniform persistence of solutions, which will require rigorous
proof of model well-posedness. Thus we reserve such questions addressing existence, regularity and
global properties of solutions for our follow-up study. We do remark here that use of abstract
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semigroup theory [35] or transformation to an age-structured model as noted in Remark 1 combined
with fixed point techniques applied to an integral form of the system, as in [8], can yield existence
and uniqueness results. In both approaches, assuming antibody-dependent rates, e.g. Λ(y), to be
L∞+ (0,∞) should be sufficient for finding unique solutions in an appropriate product space consisting
of L1+(0,∞) components of non-negative Lebesgue functions defined on (0,∞). The main challenge,
different from most structured population models but similar to [6], is to properly control the
evolution of the recovered distributions, rk(t, y), through waning (decreasing) antibody level y at
rates ωk(y). We conjecture that the proportional waning rate (exponential decay of y with lower
bound yc), given by (9), will ensure rk(t, y) remains in L
1
+(yc,∞), as we show for the equilibrium
solutions in Section 5. Restriction to Sobolev spaces can further strengthen linearized stability
results obtained later in this current section. Also, while considering the more general setting of
measures [9] can allow for Dirac delta measures for certain rates and components, it may be easier to
transform the model to equivalent ordinary differential or delay equations in the specific examples
where we utilize Dirac delta point measures.
To begin our analysis, define the total vector population, Nv(t) = Sv(t) +
2∑
k=1
Ikv (t), and total
host population as
Nh(t) =
∞∫
0
s(t, y) dy +
2∑
k,j=1
k 6=j
 ∞∫
0
∞∫
y0
ik(t, y, y0) dy dy0 +
∞∫
0
rk(t, y) dy +
∞∫
0
∞∫
y0
ikj(t, y, y0) dy dy0
 .
Proposition 3 Solutions to the system (4)-(6) remain bounded in forward time, and moreover
lim sup
t→∞
Nh(t) =
∫∞
0
Λ(y)dy
µ
, lim sup
t→∞
Nv(t) =
Λv
µv
.
Proof Consider the differential equation satisfied by Nh(t) derived from (4):
dNh(t)
dt
=
∞∫
0
Λ(y)dy − µNh(t)−
∞∫
0
s(t, y)
∑
k
βkv (y)I
k
v (t)dy
+
∑
k
∞∫
0
∞∫
y0
(
−∂(gk(y, y0)ik(t, y, y0))
∂y
− (µ+ γk(y, y0)ik(t, y, y0))
)
dydy0
+
∑
k
∞∫
0
(
∂(ωk(y)rk(t, y))
∂y
+
∫ ∞
0
γk(y, y0)ik(t, y, y0)dy0 − µrk(t, y)− βjv(y)rk(t, y)Ijv(t)
)
dy
+
∑
j 6=k
∞∫
0
∞∫
y0
(
−∂(gkj(y, y0)ikj(t, y, y0))
∂y
− (γkj(y, y0) + µ)
)
ikj(t, y, y0)dydy0
+
∑
j 6=k
∞∫
0
(
∂(ωkj(y)rkj(t, y))
∂y
+
∫ ∞
0
γkj(y, y0)ikj(t, y, y0)dy0 − µrkj(t, y)
)
dy
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Applying the fundamental theorem of calculus, along with the boundary conditions of (4) (noting
for example that ωk(y)rk(t, y) = 0 for y ≤ yc ≥ 0 and all the populations decay to zero as y →∞),
several cancellations occur and we simply obtain
dNh(t)
dt
=
∞∫
0
Λ(y)dy − µNh(t).
Similar conclusion holds for Nv(t) and the result follows.
3.1 Reproduction Number & Dynamical Properties of the Nested Systems
Define the following quantities giving the probability of host recovery and host-vector force of
infection as functions of antibody levels:
pik(y, y0) = e
− ∫ y
y0
γ(a,y0)+µ
gk(a,y0)
da
, Fk(y0) =
∞∫
y0
pik(y, y0)
gk(y, y0)
βk(y, y0) dy (15)
Then the antibody level dependent basic reproduction number for each strain is given by:
Rk0 =
Nv
µµv
∞∫
0
Λ(y0)β
k
v (y0)Fk(y0) dy0, (16)
where Nv =
Λv
µv
. Note that host-vector force of infection Fk(y0) may not mimic infection severity
measured by peak viral load within-host, as shown in Fig. 3(b) where Fk(y0) achieves maximum
levels for smaller magnitudes of pre-existent antibody level y0 than infection severity (due to de-
creasing infectious period associated with ADE).
The following proposition shows that the basic reproduction numberRk0 is a threshold for disease
extinction (locally) and existence of an endemic equilibrium.
Proposition 4 If Rk0 < 1, k = 1, 2, then the DFE E0 is locally asymptotically stable. If Rk0 > 1,
there exists a single strain boundary equilibrium Ek and E0 is unstable.
Proof For the single-strain equilibrium Ek, we derive the equilibrium equation for I¯kv :
µv
Nv − I¯kv
=
∞∫
0
Λ(y0)
βkv (y0)I¯
k
v + µ
βkv (y0)Fk(y0) dy0
Let the right-hand side of the above equation be denoted F (I¯kv ) and the left-hand side G(I¯
k
v ). Then
G is increasing on [0, Nv), approaching +∞ as I¯kv approaches Nv from the left, and F is decreasing
on [0, Nv). Note that F (0) > G(0) ⇔ Rk0 > 1. Thus there exists a positive equilibrium value I¯kv if
and only if Rk0 > 1.
Now for the stability of E0, we will consider the linearized equation for deviations of solutions:
s˜(t, y) = s(t, y) − s¯(y), i˜k(t, y, y0), r˜k(t, y), i˜jk(t, y, y0), S˜v(t) = Sv(t) − S¯v, I˜kv (t). After discarding
higher order terms in (4)-(6), we obtain the following linearized equations:
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∂s˜(t, y)
∂t
= −µs˜(t, y)− s¯(y)
∑
k
βkv (y)I˜
k
v (t)
∂i˜k(t, y, y0)
∂t
+
∂(gk(y, y0)˜ik(t, y, y0))
∂y
= − (γk(y, y0) + µ) i˜k(t, y, y0)
gk(y0, y0)˜ik(t, y0, y0) = β
k
v (y0)s¯(y)I˜
k
v (t)
∂r˜k(t, y)
∂t
− ∂(ωk(y)r˜k(t, y))
∂y
=
∫ ∞
0
γk(y, y0)˜ik(t, y, y0)dy0 − µr˜k(t, y) (17)
∂i˜kj(t, y, y0)
∂t
+
∂(gkj(y, y0)˜ikj(t, y, y0))
∂y
= − (γkj(y, y0) + µ) i˜kj(t, y, y0), i˜kj(t, y0, y0) = 0
dS˜v
dt
= −µvS˜v −Nv
 2∑
k=1
∞∫
0
∞∫
y0
βk(y, y0)˜ik(t, y, y0) dy dy0 +
2∑
k,j=1
k 6=j
∞∫
0
∞∫
y0
βkj(y, y0)˜ikj(t, y, y0) dy dy0

dI˜kv
dt
= Nv
 ∞∫
0
∞∫
y0
βk(y, y0)˜ik(t, y, y0) dy dy0 +
∞∫
y0
∞∫
y0
βjk(y, y0)˜ijk(t, y, y0) dy dy0
− µv I˜kv (18)
We assume exponential form of the deviations of solutions from E0 (using separation of vari-
ables for the PDE’s), and thus insert the following variables into the linearized system: s˜(t, y) =
sˆ(y)eλt, ik(t, y, y0) = iˆk(y, y0)e
λt, rk(t, y) = rˆk(y)e
λt, ijk(t, y, y0) = iˆjk(y, y0)e
λt, Sv(t) = Sˆve
λt, Ikv =
Iˆkv e
λt. After some simplification, we arrive at the following equations for λ ∈ C and Sˆv, Iˆ1v , Iˆ2v ∈ R+:
λSˆv = −µvS˜v −Nv
 2∑
k=1
∞∫
0
βkv (y0)s¯(y0)Iˆ
k
vL(y0) {ϕ1} (λ)dy0
 (19)
λIˆkv = −µv Iˆkv +Nv
∞∫
0
βkv (y0)s¯(y0)Iˆ
k
vL(y0) {ϕ1} (λ)dy0
where ϕk(y, y0) =
pik(y,y0)
gk(y,y0)
βk(y, y0), L(y0) {·} (λ) denotes Laplace transform (with additional vari-
able y0). The Iˆ
k
v equation above yields the characteristic equation:
1 =
1
λ+ µv
Nv
µ
∞∫
0
βkv (y0)Λ(y0)L(y0) {ϕ1} (λ)dy0 := Ψk(λ) (20)
Then Ψk(0) = Rk0 and lim
λ→∞
Ψk(λ) = 0 for λ ∈ R. Thus we readily infer that if Rk0 > 1, then E0 is
unstable since there exists eigenvalue λ > 0 corresponding to eigenvector with Iˆkv > 0. On the other
hand suppose thatRk0 < 1, k = 1, 2. Suppose by way of contradiction that there exists an eigenvalue
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with non-negative real part; λ = a + bi, a ≥ 0. Cleary that can not happen if Iˆkv = 0, k = 1, 2,
since in that case λ = −µv. So assume Iˆkv > 0. Then taking modulus of (20), we find that
1 = |Ψk(λ)| ≤ 1
λ+ µv
Nv
µ
∞∫
0
βkv (y0)Λ(y0)|L(y0) {ϕ1} (λ)|dy0 ≤ Ψk(0) = Rk0 < 1,
which gives a contradiction.
In addition to existence of unique single strain equilibria, Ek, when Rk0 > 1, when βkv is constant
(does not depend on host antibody level y0), Ek can be explicitly found to have the following positive
components:
I¯kv =
µvµ
βkv (µv +
∫∞
0
Λ(y0)Fk(y0) dy0)
(Rk0 − 1) , S¯kv = Nv − I¯kv , s¯(y) = Λ(y)µ+ βkv I¯kv ,
i¯k(y, y0) = β
k
v s¯(y0)I¯
k
v
pik(y, y0)
gk(y, y0)
, r¯k(y) =
1
ωk(y)
∞∫
y
e
y∫
a
µ
ωk(s)
ds
∞∫
0
γk(a, y0)¯ik(a, y0)dy0da. (21)
Next, we define the following host to vector “force of infection” quantities with respect to primary
and secondary infections, respectively:
Gk =
∞∫
0
Λ(y0)Fk(y0) dy0, if βkv constant, Gk =
µµv
Nvβkv
Rk0 , (22)
Hkj =
∞∫
0
1
ωk(y0)
∞∫
y0
e
y0∫
a
µ
ωk(s)
ds
∞∫
0
γk(a, z)Λ(z)
pik(y0, z)
gk(y0, z)
dzda
∞∫
y0
βkj(y, y0)
pikj(y, y0)
gkj(y, y0)
dy dy0, (23)
Note that in the absence of waning, i.e. ωk ≡ 0, then r¯k(y) is proportional to the probability density
corresponding to the antibody concentration after primary infection:
r¯k(y) =
∞∫
y0
γk(y, y0)¯ik(y, y0)
µ
dy0,
Hkj =
∞∫
0
∞∫
y0
γk(y0, z)
µ
Λ(z)
pik(y0, z)
gk(y0, z)
dz
∞∫
y0
βkj(y, y0)
pikj(y, y0)
gkj(y, y0)
dy dy0. (24)
The invasion reproduction number for strain j invading strain k is the following:
Rjinv =
Rj0
Rk0
+
1
µv
∞∫
0
βjv(y0)r¯k(y0)
∞∫
y0
βkj(y, y0)
pikj(y, y0)
gkj(y, y0)
dy dy0 (25)
Plugging in equilibrium value of r¯k(y) to (25), for the case of constant vector to host transmission
rate βkv , we obtain
Rjinv =
Rj0
Rk0
+
µvβ
j
v
(Rk0 − 1)
Rk0µv + Gk
Hkj .
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Theorem 1 Consider the case that βkv is constant (does not depend on host antibody level y0). Let
j, k ∈ {1, 2}, j 6= k and suppose that Rk0 > 1. If Rjinv < 1, then Ek1 is locally asymptotically stable.
If Rjinv > 1, then Ek1 is unstable.
Proof Without loss of generality, let k = 1, j = 2. The linearized PDE system solved with separation
of variables, similar to (19) reduces to the following equations for λ ∈ C and Sˆv, Iˆ1v , Iˆ2v ∈ R+:
λSˆv = −
µv + I¯1v ∞∫
0
s¯(y)β1vF1(y)dy
 Sˆv (26)
− S¯v
∞∫
0
[
β1v(s¯(y0)Iˆ
1
v + sˆ(y0)I¯
1
v )L(y0) {ϕ1} (λ) + β2v s¯(y0)Iˆ2vL(y0) {ϕ2} (λ)
]
dy0
− Iˆ2v
∞∫
0
(
β2v r¯1(y0)L(y0) {ϕ12} (λ) + β1v rˆ2(y0)L(y0) {ϕ21} (λ)
)
dy0
λIˆ1v = −µv Iˆ1v + S¯v
∞∫
0
β1v(s¯(y0)Iˆ
1
v + sˆ(y0)I¯
1
v )L(y0) {ϕ1} (λ) dy0
+ Iˆ2v
∞∫
0
β1v rˆ2(y0)L(y0) {ϕ21} (λ) dy0 + I¯1v
∞∫
0
s¯(y)β1vF1(y)dy
λIˆ2v = −µv Iˆ2v + S¯v
∞∫
0
β2v s¯(y0)Iˆ
2
vL(y0) {ϕ2} (λ) dy0 + Iˆ2v
∞∫
0
β2v r¯1(y0)L(y0) {ϕ12} (λ) dy0 (27)
where ϕk(y, y0) =
pik(y,y0)
gk(y,y0)
βk(y, y0), L(y0) {·} (λ) denotes Laplace transform (with additional vari-
able y0), and
sˆ(y) =
Λ(y)
λ+ µ+ β1v I¯
1
v +
∑
k β
k
v Iˆ
k
v
, rˆ2(y) =
1
ωk(y)
∞∫
y
e
y∫
a
λ+µ+β1vI¯
1
v
ωk(s)
ds
∞∫
0
β2v s¯(y0)Iˆ
2
vL(y0) {ϕ2} (λ)dy0da.
Assume that Iˆ2v > 0. Upon plugging in equilibrium values, we use that
s¯(y0)S¯v =
µvΛ(y0)
β1v
∫∞
0
Λ(y)F1(y)dy
=
NvΛ(y0)
R10µ
.
The I2v equation (27) becomes
1 =
1
λ+ µv
 Nv
R10µ
∞∫
0
β2vΛ(y0)L(y0) {ϕ2} (λ) dy0 +
∞∫
0
β2v r¯1(y0)L(y0) {ϕ12} (λ) dy0
 (28)
This yields the characteristic equation 1 = G(λ) for an eigenvalue λ where G(λ) is the right hand
side of (28). Note G(0) = R2inv and lim
λ→∞
G(λ) = 0 for λ ∈ R. Thus we readily infer that if
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R2inv > 1, then E11 is unstable since there exists eigenvalue λ > 0 corresponding to eigenvector with(
Sˆv, Iˆ
1
v , Iˆ
2
v
)
= (0, 0, 1).
Now consider the case where R2inv < 1. We claim that E11 is locally asymptotically stable. First
consider the case Iˆ2v > 0. Suppose by way of contradiction that there exists an eigenvalue with
non-negative real part; λ = a+ bi, a ≥ 0. Then taking modulus of (28), we find that
1 = |G(λ)| ≤ 1
µv
 Nv
R10µ
∞∫
0
β2vΛ(y0)|L(y0) {ϕ2} (λ)| dy0 +
∞∫
0
β2v r¯1(y0)|L(y0) {ϕ12} (λ)| dy0

≤ G(0) = R2inv < 1,
which gives a contradiction.
Next consider the case where Iˆ2v = 0. This also implies that rˆ2 = 0. Notice that all of terms
referring to strain 2 are now zero in (26), thus we drop the superscript referring to strain 1. Adding
two vector equations in (26), we obtain λ(Sˆv + Iˆv) = −µv(Sˆv + Iˆv). Therefore if Sˆv 6= −Iˆv, then
λ = −µv. So consider the case Sˆv = −Iˆv. Suppose by way of contradiction that there exists an
eigenvalue with non-negative real part; λ = a+ bi, a ≥ 0. Then after substitution and cancellation
involving the equations of (26), we obtainλ+ µv + βv I¯v ∞∫
0
F(y)s¯(y)dy
 (λ+ βv I¯v + µ) = (λ+ µ)βvS¯v ∞∫
0
s¯(y)L(y) {ϕ} (λ)dy
⇒ 1 < |λ+ βv I¯v + µ||λ+ µ| =
|βvS¯v
∞∫
0
s¯(y)L(y) {ϕ} (λ)dy)|
|λ+ µv + FβvS¯I¯v| ≤
βv
∞∫
0
F(y)s¯(y)S¯vdy
µv +
∞∫
0
F(y)s¯(y)dyβv I¯v
=
µv
µv +
∞∫
0
F(y)s¯(y)dyβv I¯v
< 1
This yields a contradiction.
3.2 Coexistence equilibrium
The complexity of the model challenges explicit formulation and conditions for a coexistence equi-
librium. However, general equations of two variables for coexistence equilibria can be derived, which
reduced to a single variable equation in the case of symmetric strains. Furthermore, when there is
no waning (ω ≡ 0), a quadratic equation determines coexistence equilibria. Thus we first consider
the case of no waning.
Case: No waning
Recall the host to vector force of infection quantities Gk and Hkj given by (22) and (24). Let
x¯k = βv I¯
k
v . Then the following equations for x¯k, k = 1, 2 can be derived for a coexistence equilibrium
(denoted by Ec):
µv
βkv
=
(
x¯jHkj
µ+ x¯j
+
Gk
µ+ x¯1 + x¯2
)(
Nv − x¯1
β1v
− x¯2
β2v
)
, j 6= k, (29)
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⇒ x¯2H21
µ+ x¯1
+
G1
µ+ x¯1 + x¯2
=
x¯1H12
µ+ x¯2
+
G2
µ+ x¯1 + x¯2
(30)
Indeed obtain the following equations for Ec from the model:
S¯kv = Nv −
∑
k
x¯k, s¯(y) =
Λ(y)
µ+
∑
k x¯k
,
i¯k(y, y0) = s¯(y0)x¯k
pik(y, y0)
gk(y, y0)
, r¯k(y) =
xk
µ+ xj
∫ ∞
0
γk(y, y0)s¯(y0)
pik(y, y0)
gk(y, y0)
dy0,
i¯kj(y, y0) = βv r¯k(y0)I¯
j
v
pikj(y, y0)
gkj(y, y0)
,
µvx¯k
βkv
= S¯vx¯k
∞∫
0
Fk(y0)s¯(y0) dy0 + S¯v x¯kx¯j
µ+ x¯k
∞∫
0
Fjk(y0)s˜k(y0) dy0,
µv
βkv
=
(
Nv − x¯1
β1v
− x¯2
β2v
) ∞∫
0
Fk(y0)Λ(y0) dy0 + (µ+ x¯1 + x¯2)x¯j
µ+ x¯k
∞∫
0
Fjk(y0)s˜j(y0) dy0
 ,
where
Fkj(y0) =
∞∫
y0
pikj(y, y0)
gkj(y, y0)
βkj(y, y0) dy, s˜k(y0) =
∞∫
0
pik(y0, z)
gk(y0, z)
Λ(z)γk(y0, z) dz.
The equations (29) and (30) follow from the definition of Gk and Hkj .
Under general parameters, the equations for the coexistence equilibrium yield a quadratic equa-
tion for x¯2 in terms of x¯1, and therefore it does not reduce to a polynomial equation in the single
variable x¯1. Thus, for tractability, we consider the case of identical strains and constant vector to
host transmission rate, i.e. βv = β
1
v = β
2
v ,G = G1 = G2,H = H12 = H21 . Then the equation (30)
simplifies to (x¯2 − x¯1)(µ + x¯1 + x¯2) = 0, which implies that x¯1 = x¯2. From (29), we obtain the
following quadratic equation for x¯ = x¯k = βv I¯
k
v :
2µv ((G +H) + µv)x2 + [µvµ(3µv + 2G)− Λvβv(G +H)]x+ (µvµ)2 (1−R0) = 0 (31)
We cannot rule out the existence two positive (subthreshold) coexistence equilibria when R0 (:=
maxk(Rk0)) < 1, known as backward bifurcation [21]. However, we can preclude existence of sub-
threshold equilibria if the second (linear) coefficient of the quadratic (31) is positive. For instance,
the following result follows from Proposition 4 and equation (31):
Proposition 5 Consider the case of symmetric strains, constant vector-host transmission and no
waning, i.e. R0 = Rk, βkv (y) = βv and ωk ≡ 0, k = 1, 2. Furthermore, assume that H ≤ G and
Λvβv < 2µvµ. If R0 < 1, then there are no endemic equilibria. If R0 > 1, then (in addition to
existence of single-strain equilibria Ek) there exists a unique coexistence equilibrium, Ec.
Note that the conditionH ≤ G in the hypothesis can be interpreted as “secondary” force of infection
is less than primary.
A coexistence equilibrium under the condition of symmetric strains, denoted by Ec, has the
following components:
I¯kv = x¯/βv, where x¯ is root of (31),
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S¯kv = Nv − I¯kv , s¯(y) =
Λ(y)
µ+ βv
∑
k I¯
k
v
, i¯k(y, y0) = βv s¯(y0)I¯
k
v
pik(y, y0)
gk(y, y0)
,
r¯k(y) =
∞∫
0
γk(y, y0)¯ik(y, y0)
µ+ βjv I¯
j
v
dy0, (32)
i¯kj(y, y0) = βv r¯k(y0)I¯
j
v
pikj(y, y0)
gkj(y, y0)
,
where the quantities Gk and Hkj , given by (22) and (24), are identical for strains k, j.
Case: Waning
In the case of continuous waning, there is no analytical solution for the coexistence equilibria.
Indeed, even for symmetric strains, the equations become transcendental, shown below:
r¯k(y) =
1
ωk(y)
∞∫
y
e
y∫
a
µ+x¯j
ωk(s)
ds
∞∫
0
γk(a, y0)¯ik(a, y0)dy0da
1
βkv
= S¯v
∞∫
0
Fk(y0)s¯(y0) dy0 + S¯vx¯j
∞∫
0
1
ωj(y0)
∞∫
y0
e
y0∫
a
µ+x¯k
ωj(s)
dsFjk(y0)s˜j(a) da dy0
µv
βkv
=
(
Nv − x¯1
β1v
− x¯2
β2v
) Gk
µ+ x¯1 + x¯2
+ x¯j
∞∫
0
Fjk(y0)
ωj(y0)
∞∫
y0
e
y0∫
a
µ+x¯k
ωj(s)
ds
s˜j(a) da dy0
 , k 6= j.
(33)
In this case, we are also not able to prove that a coexistence equilibrium, Ec, of symmetric strains
must have equal components (x¯1 = x¯2), as shown when there is no waning. The above equations
do allow for numerical approximation of roots, which we will perform for examples considered in
Section 5 in the presence of waning.
4 Numerical Scheme
We develop a finite difference scheme combined with a ODE solver in MatLab in order to numerically
solve the coupled immuno-epidemiological model. To simulate the coupled system, first consider
the within-host model ODE for relevant ranges of pre-existent antibody levels of susceptible hosts,
y1 ≤ y0 ≤ yM0 , and time since infection 0 ≤ τ ≤ τend. Here y0 supplies the variable initial condition
in within-host system (1), where other initial conditions x0, z0 are fixed. Note that the distinct
strains may have different parameter values in (1), in which case the ODE simulations must be
conducted for each strain. The mesh chosen for the interval [y1, yM0 ] can have equal or variable
step size with M0 mesh-points. The output of the ODE solver is the solution vector, denoted here
(φ(τk; ym))
N0
k=1, where (τk)
N0
k=1 is a partition of 0 ≤ τ ≤ τend for each ym, m = 1, . . . ,M0. We utilize
MatLab solver ODE45, which adaptively chooses the time partition and interpolates at time points
(τk)
N0
k=1. Consider the state variable y(τ ; ym) giving antibody level y during primary infection. It is
possible to consider the partitions (y(τk; ym))
N0
k=1 for each m = 1, . . . ,M0. For small M0, for instance
the case of susceptible point distribution (M0 = 1), this method of partitioning increases speed and
is equivalent to transforming the infected host antibody level, y, to time since infection τ , similar to
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the approach in [17]. However for M0 > 1, the number of stored y meshpoints will rapidly increase
with M0, and thus it is advantageous to utilize a “global” partition (y`)
M
`=1 which contains as a
sub-partition the initial mesh y1, . . . , yM0 and covers all necessary stored antibody variables. Then
we can interpolate the pathogen and specific antibody, x and z, as functions of y onto this global
mesh (y`)
M
`=1, in order to compute linking functions γ(y, y0), β(y, y0), gk(y, y0) at each (reachable)
grid point (y`, ym), 1 ≤ ` ≤ M, 1 ≤ m ≤ M0. The same logic is utilized for secondary infection,
along with numerical integration for reproduction numbers and equilibria values.
For the epidemiological model, we approximate solutions to the antibody-level structured PDE
vector-host model with the stored within-host calculations. Let 0 ≤ t ≤ T be the time interval of
interest and {tn}Nn=1 be a partition of 0 ≤ t ≤ T with fixed time step ∆t = T/N . In the following,
we denote the time iteration, n, in the superscript of state variables and the antibody levels as
function arguments, e.g. Ik,nv , i
n+1
k (y`, ym). For clarity, we utilize antibody variables (y`, ym) in
function arguments, but note that the outer state variables and linking parameters are computed
at (reachable) grid points in within-host part of numerical scheme. The numerical algorithm for
approximating solutions at times tn, n = 1, . . . , N , is the following:
Ink =
M0∑
m=1
M∑
`=1
βk(y`+1, ym+1)i
n
k (y`+1, ym)∆y`∆ym, Injk =
M∑
i=1
M∑
`=1
βjk(yi+1, y`+1)i
n
jk(yi+1, y`+1)∆yi∆y`,
Sn+1v =
Snv + Λv∆t
1 +∆t
(
µv +
2∑
k,j=1
k 6=j
Ink + Injk
) , Ik,n+1v = Ik,nv +∆tSn+1v (Ink + Injk)1 +∆tµv
sn+1(ym) =
sn(ym) +∆tΛ(ym)
1 +∆t
(
2∑
k=1
βkv (ym)I
k,n+1
v + µ
) ,
in+1k (ym, ym) =
βkv (ym)
gk(ym, ym)
Ik,n+1v s
n+1(ym),
in+1k (y`+1, ym) =
mnk (y`+1, ym+1) +
∆t
∆y`
gk(y`, ym)i
n+1
k (y`, ym)
1 +∆t
(
gk(y`+1,ym)
∆y`
+ γk(y`+1, ym) + µ
) ,
rn+1k (yM−`) =
rnk (yM−`) +∆t
(
ωk(yM−`)
∆yM−`
rn+1k (yM−`+1) +
M∑
i=1
γk(yM−`, yi)in+1k (yM−`, yi)∆yi
)
1 +∆t
(
ωk(yM−`+1)
∆yM−`
+ β2v(yM−`)I
2,n+1
v + µ
) ,
in+1jk (y`, y`) =
βkv (y`)
gjk(y`, y`)
Ik,n+1v r
n+1
j (y`),
in+1jk (yi+1, y`) =
injk(yi+1, y`+1) +
∆t
∆yi
gjk(yi, y`)i
n+1
k (yi, y`)
1 +∆t
(
gjk(yi+1,y`)
∆yi
+ γjk(yi+1, y`) + µ
) ,
where i, `,m denote index for discretized antibody level during secondary infection, during and after
recovery of primary infection, and before primary infection, respectively, with 1 ≤ i ≤ M, 1 ≤ ` ≤
M, 1 ≤ m ≤ M0 being the ranges of allowed antibody level, and j, k denote distinct strains. Note
that we utilize an implicit-explicit approximation mixture in the above finite difference scheme.
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In particular, the calculation procedure allows for implicit terms involving components that have
already been updated, thereby gaining advantages of an implicit form without having to pay the
computational price of matrix inversion (which is common with implicit schemes). We remark that
an explicit-implicit mixture approach has been used for the approximation of size-structured models
[1]. In the appendix, we present several numerical tests of rates of convergence for the algorithm
described here.
5 Epidemiological Implications
In this section, we consider examples and potential implications for vaccination, utilizing formulas
established in Section 3 and the numerical scheme developed in Section 4. First, we point out an
important severity measure for dengue; the prevalence of DHF. Define the measure of DHF in the
population of strain-k infected individuals by the following:
Dk(t) =
∞∫
0
∞∫
y0
1{x(τ)>Vc} (ik(t, y, y0) + ijk(t, y, y0)) dy dy0 =
y˜u∫
y˜l
yu∫
yl
(ik(t, y, y0) + ijk(t, y, y0)) dy dy0,
(34)
where the constant Vc is a threshold critical lower bound such that if viral load during infection, x(τ),
is above Vc, the patient will experience DHF. The right hand side of the above equation reflects that
this will translate into a particular range of antibody level, yl ≤ y ≤ yu, and a particular window of
pre-existent antibody level, y˜l ≤ y0 ≤ y˜u, which will precipitate DHF. A related measure which can
be useful is the incidence of individuals who will experience DHF (by strain-k) at time t predicated
on their initial antibody level at time of infection:
Ik(t) = Iv(t)
y˜u∫
y˜l
βkv (y0) (s(t, y0) + rj(t, y0)) dy0, (35)
In the following examples, we perform numerical simulations utilizing the derived equilibria formulae
and numerical scheme for solutions of the model. In order to simplify the model for numerical
validation, we assume symmetric strains. We fix parameter values, except for waning rate (ρ(y)),
vector-host transmission rate (βv(y)) and susceptible recruitment rate (Λ(y)), in order to compare
simulations for cases with or without waning, temporary cross-immunity, and a distribution of
susceptible antibody level.
5.1 No Waning
In the first example, we consider the case where there is no waning, i.e. ωk(y) ≡ 0. Although
cross-reactive antibody levels are thought to decline after primary, the absence of waning may
be a reasonable approximation for Dengue endemic regions. In particular, some studies have found
antibody levels to be stable because of continual exposure to Dengue providing boosting of immunity
[24]. The explicit inclusion of boosting through exposure to virus as in [6] would significantly
complicate the model and is beyond the scope of the current paper. Here, we assume constant vector-
host transmission rate (βv(y) ≡ βv) and susceptible point distribution, i.e. Λ(y) = Λδ(ys), s(0, y) =
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Fig. 4 Numerical Simulations for the case of no waning (a),(c),(e), and for case of waning and temporary cross-
immunity (b),(d),(f). Here, we utilize a point distribution for susceptible antibody level Λ(y) = Λδ(ys), S(0, y) =
S0δ(ys), with ys = 0.11, along with all other within-host and linking parameters as in Figs 1 and 3. The demographic
parameters are Λ = 100, Λv = 0.02, µ = 1/(10× 365), µv = 1/20. The vector-host transmission rate βv(y) is constant
with βv = 0.00025 in (a,c,e) and piecewise constant given by (38) with βv = 0.00025, yp = 2 in (b,d,f). The waning
rate in (a,c,e) is ω(y) = 0 and is given by (9) with ξ = 0.002, yc = 0.02. Additionally, we let the viral load threshold
for infected individual to experience DHF in (34) to be Vc = 30, which generates the vertical dashed lines in (e), (f)
giving the antibody level window of DHF risk.
S0δ(ys). Observe Figures 4(a), 4(c), 4(e) displaying simulations of time-dependent solutions of
infected vectors and hosts, and the final time distribution of recovered and secondary infected
individuals with respect to antibody level y and y0, respectively. Calculations of equilibria are also
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displayed, and note the long time for convergence, along with some numerical error. In this case
without waning, the vast majority of recovered individuals have a large cross-reactive antibody
level, whereby secondary exposure leads to mild infection.
5.2 Waning and temporary cross-immunity
For examples in this and the next section, we consider particular forms of waning, ωk(y) and
antibody dependent vector-host transmission rate βkv (y), motivated by epidemiological observations.
We utilize the form of waning given ωk(y) = ξ(y − yc), which is consistent with a lower bound yc
and exponential decline of antibodies as formulated in equation (9). In this case, inserting (9) into
(21), we find the (strain-k) recovered equilibrium component
r¯k(y) =
(y − yc)
µ
ξ−1
ξ
∞∫
y
(a− yc)−
µ
ξ
∞∫
yc
γk(a, y0)¯ik(a, y0)dy0da,
with
∞∫
yc
r¯k(y) =
1
µ
∞∫
yc
∞∫
0
γk(y, y0)¯ik(y, y0)dy0dy. (36)
Note the the total amount of recovered individuals obtained by the integration above (36) is precisely
the number at the equilibrium with no waning (24). In the instance of recovery occurring at a
constant level of antibody y∗ (12), we obtain
r¯k(y) =
(y − yc)
µ
ξ−1
ξ
(y∗ − yc)−
µ
ξ
∞∫
0
i¯k(y∗, y0)dy0. (37)
Observe that recovered individuals at the lower bound of antibody level satisfies r¯k(yc) = 0 when
µ > ξ (natural death rate greater than waning rate), and r¯k(yc) = +∞ when µ < ξ, however the
total amount of recovered individuals stays finite by (36).
Furthermore, as mentioned previously, primary Dengue infection induces a period of temporary
cross-immunity. The simplest way to include this feature is to assume that
βkv (y) = β
k
v1{y<yp} =
{
0 y ≥ yp
βkv y < yp
, (38)
so that the vector to host transmission rate is a piecewise function where there exists a threshold
antibody level yp providing complete protection above it. In this case, let ck := rk1{y≥yp} and
sk := rk1{y<yp}, denoting density of recovered individuals with cross-immunity and susceptible to
secondary infection, respectively. From (4), we derive
∂ck(t, y)
∂t
− ∂(ωk(y)ck(t, y))
∂y
= 1{y≥yp}
∫ ∞
0
γk(y, y0)ik(t, y, y0)dy0 − µrk(t, y), (39)
∂sk(t, y)
∂t
− ∂(ωk(y)sk(t, y))
∂y
= 1{y<yp}
∫ ∞
0
γk(y, y0)ik(t, y, y0)dy0 − µsk(t, y)− βjv(y)sk(t, y)Ijv(t),
sk(t, yp) = ck(t, yp), ωk(yc)sk(t, yc) = lim
y→∞ωk(y)ck(t, y) = 0. (40)
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Previous results requiring constant vector-host transmission βkv , in particular Theorem 1, Propo-
sition 5 and explicit equilibria formulas (21) and (32), can be extended to this case of piecewise
constant βkv (y). To see this first note that for integrals in the formulae for Rk,Rkinv and equilibria,
the upper limit of integration yp will appear (in place of∞) wherever βkv (y) appears. Also for Rkinv,
r¯k(y) can be replaced by s¯k(y), which makes the arguments in proof of Theorem 1 work for this
case of piecewise constant βkv (y). Furthermore for the symmetric coexistence equilibrium (32), the
recovered equation formulas will be altered as follows:
c¯k(y) =
1
ωk(y)
∞∫
y
exp
 y∫
a
µ
ωk(s)
ds
 yp∫
0
γk(a, y0)¯ik(a, y0)dy0da, y ≥ yp
s¯k(y) =
1
ωk(y)
yp∫
y
exp
 y∫
a
µ+ βjv I¯
j
v
ωk(s)
ds
 yp∫
0
γk(a, y0)¯ik(a, y0)dy0da+
ωk(yp)
ωk(y)
c¯k(yp) exp
 y∫
yp
µ+ βjv I¯
j
v
ωk(s)
ds
,
where y < yp for the domain of s¯k(y). The secondary vector-host force infection at equilibrium
then depends upon s¯k(y). The component rk(y) in boundary equilibrium remains as is in (21)
(with upper limit of integration yp), as can be seen in the above formula when removing secondary
infection (Ijv = 0), where rk = ck + sk.
In numerical simulations, we first consider the case of susceptible point distribution (Λ(y) =
Λδ(ys), S(0, y) = S0δ(ys)). We compute time dependent solutions from initial conditions corre-
sponding to outbreak initiation, which are shown in Figures 4(b), 4(d), 4(f). Observe how waning
and temporary cross-immunity shape the distribution of recovered and secondary infected individ-
uals with respect to y in this example, as opposed to the previous case with constant vector-host
transmission and no waning. In particular, the waning allows for secondary infected cases in the
window of antibody level causing DHF, resulting in around 2 DHF cases per time unit instead
of zero in previous case without waning. Note that since there is only one susceptible antibody
level, the variable step size partition of antibody level y (equivalent to transforming y to time-since-
infection τ with fixed step size in τ) is advantageous for reducing error, as described in Section 4.
In contrast for the next simulation where Λ(y) is a distribution, we utilize the fixed antibody level
(∆y) step size partition combined with interpolation of the within-host ODE solver output on to
this partition (see Section 4).
5.3 Heterogeneity among susceptible antibody level
In this section, for the (initial) distribution of susceptible antibody level given by Λ(y), we choose
the symmetric truncated normal distribution with support on the interval [ym − α, ym + α] (insert
in Figure 7(a)). First, in Fig. 5, we display calculations of equilibrium recovered and secondary
infected distributions for two different cases of waning rates (ξ), µ > ξ and µ < ξ (µ is host death
rate), displaying different limiting behavior as antibody level y approaches lower bound yc. Note
that we analytically derived this limit dichotomy in (37), and larger waning (µ < ξ) corresponds to
larger accumulation of individuals in DHF risk window before r¯1(y)→∞ as y ↘ yc in this case.
Next we perform simulations utilizing the finite difference and multi-scale method outlined in
Section 4. The numerical solutions (shown in Figure 6) are computationally more expensive due
to the distribution (with width 2α) of susceptible antibody level. Comparing to the previous case
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Fig. 5 Equilibria recovered host density distribution (blue curve) and total secondary infected cases (red curve) with
respect to initial antibody size y0 for distinct cases, when waning rate is constant ξ, the transmission rate βv(y) is
constant (describing temp. cross immunity), µ > ξ, recovery rate is chosen as: γ(y, y0) = e−ρx(τ)1{fk(τ)<0}, and
susceptible antibody distribution s¯(y0) is truncated normal. (a) Death rate larger than waning rate (µ > ξ) leads to
recovered distribution r¯(y) to go to zero as y ↘ yc, (b) On the other hand if µ < ξ, r¯(y) goes to ∞ as y ↘ yc. Other
parameters, besides ξ, γ(·), µ are same as in Fig. 6.
of susceptible point distribution at ym, the number of DHF cases increases to eventually around 8
per unit time, however this may partially be due to the altered numerical algorithm which utilizes
interpolation and fixed step size ∆y. Observe how the current and pre-existent antibody levels in
recovered and secondary infected populations, respectively, evolve with time after initial outbreak
in Fig. 6(c) and 6(d). In particular, individuals with pre-existent susceptible antibody levels recover
with a certain boosted antibody level offering temporary cross-immunity until waning spreads re-
covered individuals’ antibody levels to intermediate levels at risk of DHF with accumulation at
smaller antibody titres for the chosen parameter regime, resulting in secondary and DHF cases.
For the last set of numerical simulations, we consider how shifting the mean antibody level in a
naive susceptible population affects disease incidence, especially DHF cases, upon introduction of
both Dengue strains. In this way, we investigate how population level antibody level can determine
risk of severe dengue infection. In particular, this can help explore the consequences of a Dengue
vaccination boosting cross-reactive antibody levels. As before, consider the distribution of suscep-
tible antibody level (given by Λ(y)) as the symmetric truncated normal distribution with support
on the interval [ym − α, ym + α] (Fig. 7(a)). Fixing α, we vary the mean antibody level ym and
calculate reproductive numbers, along with (severe) DHF cases at coexistence equilibrium Ec and
initial DHF transmission level.
Observe that R0 is unimodal with respect to ym, initially increasing, peaking at a relatively
small antibody level and then decaying as the population antibody level increases further (Fig.
7(a)), as opposed to invasion reproduction number Rinv which is decreasing (Fig. 7(b)). The initial
rise in R0 follows from the host-vector transmission, as found in Fig. 3(b), caused by increasing
within-host peak viral load from ADE. However, decreasing infectious period also occurs with the
increasing viral load leading R0 to peak at smaller antibody level than the observed absolute
maximum in DHF cases (Fig. 7(a)). Here the total DHF cases, calculated at equilibrium Ec in the
immuno-epidemiological model for each ym, bears some resemblance the unimodal shape of peak
viral load on the within-host scale (Fig. 1(c)), but there are more “across-scale” forces to decipher.
In particular, first there is a local maximum caused by an overall peak in cases at maximal R0.
Next, population antibody levels rise to the intermediate window where ADE causes severe primary
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Fig. 6 Numerical simulations in the case of susceptible antibody distribution as symmetric truncated normal having
support on [ym − α, ym + α] (Fig. 7(a)) where ym = 0.11 and α = 0.03, along with initial conditions I1v (0) = 0.025,
I2v (0) = 0.02 and other components starting at (disease-free equilibrium) E0 (outbreak scenario). (a) Total infected by
strain k versus time; (b) Secondary infected and DHF cases versus time; (c) Density of (strain 1) recovered individuals
with respect to antibody level y, r1(t, y), evolving with time t; (d) density of secondary infected individuals with
pre-existent antibody level y0 (imported from population r1(t, y0) at time of infection) as function of t.
infection leading to a second (much larger) peak in DHF cases. However the decreasing R0 applies
an opposing dampening force on total equilibrium DHF cases, and thus the absolute maximum in
DHF cases occurs around ym = 0.2, whereas the maximum peak viral load on the within-host scale
(Fig. 1(c)) occurs around y0 = 0.5. The sharp rise in DHF cases as a function of ym to the second
maximum is caused by primary infections, as the DHF cases from secondary infections (Fig. 7(c))
is relatively small and peaks around ym = 0.1 for the chosen parameters.
Even though DHF cases at Ec decreases to zero at around ym = 0.52 when R0 becomes less
than one, the rate of initial DHF cases per infected vector in a susceptible population is large and
at maximum value for all ym ∈ [y˜` + α, y˜u − α] (when Λ(y) has support in the window of antibody
level causing DHF), which is centered around ym = 0.5, as shown in Fig. 7(d). Here we measure this
rate of initial DHF cases by βvµv
∫ y˜u
y˜l
Λ(y)dy. Thus, there can be a conflict between reduction or even
elimination/prevention of dengue cases by a cross-reactive antibody boosting vaccine administered
to a naive population and a (possibly temporary) rise in DHF cases. Since DHF cases can cause
death and should be avoided, an effective Dengue vaccine would need to boost antibody levels of
vaccinated individuals to a sufficiently large level. This can be achieved by increased vaccine efficacy
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Fig. 7 Epidemiological quantities (R0,Rinv) and disease incidence (DHF) versus immune antibody (y) distri-
bution among susceptible population with mean antibody level, ym. Susceptible (naive individuals) recruitment rate,
Λ(y), is chosen as symmetric truncated normal distribution on [ym − α, ym + α] with mean ym. In the simulations
here, we fix α = 0.03 and vary ym, in order to compute (a) basic reproduction number R0 (blue solid line), and
DHF cases at coexistence equilibrium Ec (orange solid line), (b) invasion reproduction number Rinv , (c) secondary
infected DHF cases at Ec, (d) DHF cases per infected vector in a (naive) susceptible population.
or only vaccinating individuals with large enough pre-existent antibody levels (from prior exposure
to Dengue) that can be boosted past the intermediate window of DHF risk.
6 Discussion
In this paper, we develop an immuno-epidemiological model of Dengue tracking dynamic host
cross-reactive antibody levels through infection by multiple strains and waning, which affect the
overall infection trajectory and severity across the within-host and between-host scales. The model
recapitulates: (i) how intermediate levels of preexistent cross-reactive antibodies enhance infection
within a host, and (ii) how to scale up to distributions of antibody levels among epidemiological
classes in the host population to determine risk of DHF prevalence. The system is novel in its
multi-scale connection of host immunity and infectious disease dynamics, and provides a unified
model of Dengue with ADE phenomenon.
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Our mathematical model consists of two linked systems, namely immunological (within-host)
and epidemiological (between-host). First, we formulate ordinary differential equations describing
dynamics of virus and immune response for primary or secondary Dengue infection. The model is
motivated by experimental and epidemiological evidence that certain levels of pre-existent cross-
reactive antibodies cause the more severe DHF infection. Indeed, we show that our inclusion of
distinct binding and neutralizing kinetics with ADE phenomenon in cross-reactive IgG (memory
antibodies), along with neutralizing specific IgG, induce severe infection solely by varying pre-
existent cross-reactive IgG in an intermediate window of concentration.
Next, we connect the within-host dynamics to population scale through a hybrid ODE-PDE
vector-host system structured by host antibody level. Several features of the linking and model
structure are distinguished from prior work:
– The epidemic model is size-structured with respect to a within-host immune variable as opposed
to the infection age utilized in most immuno-epidemiological studies. The one-to-one relationship
between cross-reactive memory antibodies (y(τ)) and infection age τ allows us to formulate
epidemiological parameters as functions of within-host variables, similar to [17].
– Immune status, in particular antibody level, is traced through multiple infections by distinct
strains and waning during recovery stage, with across-scale feedback on within-host and between-
host dynamics.
– Heterogeneity in immune response among susceptible individuals given by preexistent antibody
level distribution. Different from [30], our structuring variable for susceptible population is
dynamic through epidemiological stages described above.
The interplay across scales between host immunity and infection severity exhibited in Dengue
induced by ADE motivate the above characteristics of our modeling framework.
On the epidemiological scale, in addition to boundedness of solutions, certain threshold dynamics
are determined by strain (basic) reproduction number Rk and invasion reproduction number Rjinv,
and these quantities depend upon within-host variables. By linearizing the system around disease-
free and single-strain equilibria, we show that local stability is sharply determined by Rk or Rjinv.
Furthermore, we derive the formula for a unique coexistence equilibrium Ec in the case of no waning
and a transcendental equation for existence of Ec when waning occurs, under the assumption of
symmetric strains. Lastly, for certain choices of vector-host transmission βv(y) and waning rates
ρ(y) representing temporary cross-immunity and exponential decay of antibodies, we obtain explicit
formula for equilibria. Further results are difficult given the model complexity; for instance there
may be backward bifurcation preventing global stability of disease-free equilibrium. Future work
will explore stronger analytical results such as uniform persistence of strain j when Rjinv > 1.
Moreover, we construct a multi-scale numerical scheme in order to verify the equilibria calcula-
tions and to determine DHF risk landscape in different scenarios. To accomplish this, we develop
a finite difference algorithm combined with numerical solutions of ODE (Runge-Kutta method)
and numerical integration of antibody dependent functions in order to simulate the model on both
scales. The complexity of the intertwined systems challenges efficient numerical computation. In-
deed, the combination of heterogeneity in susceptible antibody distribution, and tracking antibody
levels through recovery, waning and re-infection, leads us to utilize interpolation of within-host ODE
numerical solutions nested in the discretized size-structured epidemic model. The resulting error
magnifies with increasing antibody step size ∆y, causing an unavoidable tradeoff between speed
and accuracy. It may be possible to efficiently transform the problem to infection-age structured
system (with sufficiently small number of meshpoints), as we did for the homogenous susceptible
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antibody distribution (point distribution). Future work will explore this idea, along with employing
higher order finite difference methods to increase accuracy of numerical solutions.
The numerical simulations suggest that waning after primary infection can lead to a buildup of
individuals with antibody levels in risk window for DHF upon secondary infection with a distinct
strain. Different from prior Dengue epidemic modeling studies with ADE, DHF is not simply caused
by secondary infection, rather it depends upon preexistent cross-reactive antibody titre, as shown
in biological literature. The model allows us to calculate the exact distribution of host population
under risk for severe infection, along with DHF prevalence. Indeed, by varying the mean of sus-
ceptible antibody level distribution (ym), we observe that the reproduction numbers are decreasing
in precisely the window of ym where DHF prevalence is rising. This suggests there can be conflict
between reduction or even elimination of dengue cases by cross-reactive antibody boosting vaccine
administered to naive population and a rise in DHF cases. An effective Dengue vaccine would need
to boost antibody levels to sufficiently large level to avoid increased DHF incidence which can lead
to fatalities.
Future work can build upon the epidemiological implications by explicitly incorporating vacci-
nation into the model to inform Dengue vaccine policy. The controversy surrounding apparent rise
in DHF among certain vaccinated individuals after a vaccination campaign [4,40] and questions
into how to safely vaccinate Dengue-at-risk populations, motivates the need for predictive mod-
eling frameworks including effects of targeted vaccination on population antibody levels. Such a
model would also require robust parameter estimation and identifiability analysis extending prior
work in multi-scale data fitting [36]. Ideally, the model may suggest whom to target for vaccination
dependent on cross-reactive antibody level measured by blood samples, in order to prevent DHF
incidence and ultimately eradicate the disease.
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Appendix: Numerical Convergence Rates
In this section, we provide tables showing computed rates and order of convergence for numerical
experiments of the finite difference and multi-scale simulation procedure described in Section 4. For
the numerical tests, we calculate the error in norm between computed solutions of the t, y stepping
method at certain step sizes ∆t, h = ∆y and reference solutions at some final time t = T . We utilize
three different types of reference solutions: (i) the numerically approximated equilibrium given by
our derived formula (33), (ii) solution of the numerical scheme with smallest step sizes ∆t, h˜ = ∆y,
and (iii) solution of the numerical scheme with step sizes multiplied by factor of 1/2, ∆t2 ,
h
2 . For each
error calculation at step size h, eh, we form a sequence by successively decreasing step size by 1/2,
whereby we compute order of convergence by log2(eh/eh/2). Furthermore, we consider two different
scenarios: (a) we start the initial condition where infected vectors, I1v , I
2
v are slightly perturbed from
E0 (outbreak scenario) with final time T = 50 days, (b) we start the initial condition at numerically
calculated equilibrium with final time T = 500 days. For the former scenario (a), we do not use
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numerically calculated equilibrium as a reference solution since this may be far off from simulation
at t = 50.
We compute the different orders of convergence because here are several sources of error and
to test different initial condition scenarios. Our method relies on distinct algorithms in addition to
the finite difference scheme, such as Runge-Kutta method for within-host ODE (ode45 in MatLab),
interpolation, integration and, in the case of numerical equilibrium formula, nonlinear root-finding.
Each routine can produce error, which can also propagate in the form of discontinuities in recovered
distribution corresponding to an influx of recovery from primary infected individuals with pre-
existent antibody levels at a certain mesh points from the initial susceptible antibody distribution.
In order to efficiently reduce error we utilize the trapezoidal integration when integrating with
respect to initial susceptible antibody level y0, but left endpoint integration for other antibody
variables since there is small number of mesh points (M0) for s(·, y0) when compared to the range
of antibody levels after infection and waning. We do also provide one numerical test with only left-
endpoint integration shown in last two tables, which gives more error than trapezoidal, but has more
regular order of convergence pattern. In addition, we include comparisons with a larger step size
(∆y = 0.06) for scenarios (a) and the last two tables, which forces a point distribution for susceptible
antibody levels, creating different error structure. Overall, from the different numerical tests, we
observe convergence to certain error rates within a particular compartment and/or test scenario,
ranging from orders that are sub-linear (< 1) to larger than quadratic (> 2). When comparing with
reference solutions computed by numerical simulation at smaller step size, the order of convergence
is mostly faster than linear.
Table 5 Error analysis of ih1 (50, y, y0) with initial I
1
v (0) = I
2
v (0) = .02, and other components starting at E0, for
step size ∆y = h compared to reference solution ih˜1 (h˜ =
.00375
2
) and i
h/2
1 , respectively, in L
1 norm.
∆t h = ∆y
∥∥∥ih1 − ih˜1∥∥∥ order ∥∥∥ih1 − ih/21 ∥∥∥ order
0.02 0.03 524.6908885 91.15745068
0.01 0.015 270.1464444 0.957726043 88.82019677 0.037472811
0.005 0.0075 102.1797402 1.402632521 52.36309638 0.762337357
0.0025 0.00375 27.53347556 1.891850535 27.53347556 0.927363678
Table 6 Error analysis of ih12(50, y, y0) with initial I
1
v (0) = I
2
v (0) = .02, and other components starting at E0, for
step size ∆y = h compared to reference solution ih˜12 (h˜ =
.00375
2
) and i
h/2
12 , respectively, in L
1 norm.
∆t h = ∆y
∥∥∥ih12 − ih˜12∥∥∥ order ∥∥∥ih12 − ih/212 ∥∥∥ order
0.04 0.06 0.675368267 0.006352265
0.02 0.03 0.258213027 1.38711261 0.157617642 -4.633
0.01 0.015 0.064940472 1.991372007 0.045005349 1.808260627
0.005 0.0075 0.013576682 2.257986926 0.010354484 2.119840769
0.0025 0.00375 0.002644786 2.359908155 0.002644786 1.969032926
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Table 7 Error analysis of rh1 (50, y) with initial I
1
v (0) = I
2
v (0) = .02, and other components starting at E0, for step
size ∆y = h compared to reference solution rh˜1 (h˜ =
.00375
2
) and r
h/2
1 , respectively, in L
1 norm.
∆t h = ∆y
∥∥∥rh1 − rh˜1∥∥∥ order ∥∥∥rh1 − rh/21 ∥∥∥ order
0.04 0.06 199.170148 19.71504953
0.02 0.03 153.0385939 0.380105906 132.3873372 -2.747395896
0.01 0.015 87.31621564 0.809574014 81.85961804 0.693541296
0.005 0.0075 37.51280945 1.218866289 35.05161783 1.223670901
0.0025 0.00375 15.17871831 1.305333341 15.17871831 1.20743106
Table 8 Error analysis of I1,hv (50) with initial I
1
v (0) = I
2
v (0) = .02, and other components starting at E0, for step
size ∆y = h compared to reference solution Ih˜v (h˜ =
.00375
2
) and I
h/2
v , respectively, in L
1 norm.
∆t h = ∆y
∥∥∥Ihv − I h˜v ∥∥∥ order ∥∥∥Ihv − Ih/2v ∥∥∥ order
0.04 0.06 0.011545595 0.000253176
0.02 0.03 0.011798771 -0.031294078 0.002043507 -3.012833819
0.01 0.015 0.009755265 0.274383701 0.003205022 -0.649287231
0.005 0.0075 0.006550243 0.574632587 0.003355452 -0.066172867
0.0025 0.00375 0.003194791 1.035826728 0.003194791 0.07078528
Table 9 Error analysis of sh(50, y) with initial I1v (0) = I
2
v (0) = .02, and other components starting at E0, for step
size ∆y = h compared to reference solution sh˜ (h˜ = .00375
2
) and sh/2, respectively, in L1 norm.
∆t h = ∆y
∥∥∥sh − sh˜∥∥∥ order ∥∥sh − sh/2∥∥ order
0.04 0.06 332.6520601 41.58150751
0.02 0.03 62.96919952 2.401295736 132.3873372 -1.670751168
0.01 0.015 49.82665921 0.33772848 81.85961804 0.693541296
0.005 0.0075 32.64463389 0.610071986 35.05161783 1.223670901
0.0025 0.00375 15.64718881 1.060942377 15.17871831 1.20743106
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Table 10 Error analysis of ih1 (500, y, y0) with initial condition set at numerically calculated equilibrium i¯1(y, y0)
for step sizes ∆y = h compared to i¯1, reference solution ih˜1 (h˜ = .00375) and i
h/2
1 , respectively, in L
1 norm.
∆t h = ∆y
∥∥ih1 − i¯1∥∥ order ∥∥∥ih1 − ih˜1∥∥∥ order ∥∥∥ih1 − ih/21 ∥∥∥ order
0.02 0.03 324.5169207 47.41855063 36.62544876
0.01 0.015 196.0711709 0.726916278 6.727908881 2.817221495 5.311540273 2.785644248
0.005 0.0075 105.7195462 0.891135289 0.846383875 2.99077412 0.846383875 2.649746236
0.0025 0.00375 56.5106755 0.903646798
Table 11 Error analysis of ih12(500, y, y0) with initial condition set at numerically calculated equilibrium i¯12(y, y0)
for step sizes ∆y = h compared to i¯12, reference solution ih˜12 (h˜ = .00375) and i
h/2
12 , respectively, in L
1 norm.
∆t h = ∆y
∥∥ih12 − i¯12∥∥ order ∥∥∥ih12 − ih˜12∥∥∥ order ∥∥∥ih12 − ih/212 ∥∥∥ order
0.02 0.03 8.783517629 6.042508363 3.481283278
0.01 0.015 4.503971602 0.963601096 1.631284321 1.88913931 1.082280827 1.685544319
0.005 0.0075 2.240824134 1.007168304 0.32158709 2.342726861 0.32158709 1.7507935
0.0025 0.00375 1.175949762 0.930202999
Table 12 Error analysis of rh1 (500, y) with initial condition set at numerically calculated equilibrium r¯1(y) for step
sizes ∆y = h compared to r¯1, reference solution rh˜1 (h˜ = .00375) and r
h/2
1 , respectively, in L
1 norm.
∆t h = ∆y
∥∥rh1 − r¯1∥∥ order ∥∥∥rh1 − rh˜1∥∥∥ order ∥∥∥rh1 − rh/21 ∥∥∥ order
0.02 0.03 618.0541417 775.4388502 599.9811402
0.01 0.015 461.0633089 0.422768362 356.8297922 1.119776945 285.8162025 1.069829449
0.005 0.0075 392.9077021 0.230774413 143.9789694 1.309377976 143.9789694 0.989229606
0.0025 0.00375 357.6509033 0.135638364
Table 13 Error analysis of I1,hv (500) with initial condition set at numerically calculated equilibrium I¯v for step
sizes ∆y = h compared to I¯v , reference solution Ih˜v (h˜ = .00375) and I
h/2
v , respectively.
∆t h = ∆y
∣∣Ihv − I¯v∣∣ order ∣∣∣Ihv − I h˜v ∣∣∣ order ∣∣∣Ihv − Ih/2v ∣∣∣ order
0.02 0.03 0.006679126 0.00106215 0.0008444
0.01 0.015 0.007472821 -0.161993635 0.00021775 2.286242828 0.000181798 2.215591493
0.005 0.0075 0.007599984 -0.024343416 3.60E-05 2.598522051 3.60E-05 2.338184328
0.0025 0.00375 0.007596424 0.000675948
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Table 14 Error analysis of sh(500, y) with initial condition set at numerically calculated equilibrium s¯(y) for step
sizes ∆y = h compared to s¯, reference solution sh˜ (h˜ = .00375) and sh/2, respectively, in L1 norm.
∆t h = ∆y
∥∥sh − s¯∥∥ order ∥∥∥sh − sh˜∥∥∥ order ∥∥sh − sh/2∥∥ order
0.02 0.03 462.4651032 45.73632432 33.06512108
0.01 0.015 518.3459247 -0.164570714 78.8058773 -0.784962803 31.29116995 0.079554584
0.005 0.0075 526.9051322 -0.023628012 47.51537534 0.729908803 47.51537534 -0.602638825
0.0025 0.00375 526.0055158 0.002465304
Table 15 Error analysis with initial condition set at numerically calculated equilibrium Ec for step sizes ∆y = h
compared to Ec, using left-end point approximation integration.
∆t ∆y s(500, y) Order i1(500, y, y0) Order i12(500, y, y0) Order
0.4 0.06 660.9536 14.97353256 32.78271708
0.2 0.03 2696.278157 -2.028348437 1830.012949 -6.933295423 34.9009843 -0.090332293
0.1 0.015 1728.915761 0.64110176 641.6430016 1.51201112 12.19733364 1.516701918
0.05 0.0075 1078.164779 0.68128989 214.2830149 1.582253332 4.159619189 1.552042445
0.025 0.00375 695.6780402 0.632086 74.63216773 1.521648004 1.541971374 1.431675474
Table 16 Error analysis with initial condition set at numerically calculated equilibrium Ec for step sizes ∆y = h
compared to Ec, using left-end point approximation integration.
∆t ∆y r1(500, y) Order I
1
v (500) Order
0.4 0.06 2522.062793 0.001742764
0.2 0.03 2166.277168 0.582119138 0.038248294 -4.455946151
0.1 0.015 1559.573153 0.694509637 0.024707943 0.63042051
0.05 0.0075 1167.784572 0.667748654 0.015523692 0.670503164
0.025 0.00375 942.6623956 0.619407636 0.010085476 0.622192549
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